单药与双联抗血小板治疗对药物洗脱支架植入术后血管内皮功能及炎症因子的影响

doi:10.3969/j.issn.1006-6233.2018.02.014

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1667 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of different antiplatelet regimens on vascular endothelial function and inflammatory factors after drug-eluting stent implantation. Methods: 300 patients with coronary heart disease and came to our hospital for drug eluting stent implantation from January 2015 to December 2016 were enrolled and randomly divided into monotherapy group and dual antiplatelet therapy group. Monotherapy group receive clopidogrel antiplatelet treatment whereas dual antiplatelet therapy group receive clopidogrel plus aspirin in the treatment. The vascular endothelial function indexes such as ET-1, NO and inflammatory factors such as TNF-a, IL-1, CRP were compared between the two groups at the time before operation, 12 hours after operation and 30 days after operation. Results: After operation, the levels of ET-1, TNF-a and CRP increased significantly, and NO decreased significantly. After 30 days antiplatelet treatment, the levels of ET-1, TNF-a and CRP decreased, and NO increased. Besides, ET-1 and CRP levels in dual antiplatelet therapy group were less than monotherapy group at 30 days after operation and they change more in dual antiplatelet therapy group. Level of TNF-a showed no significant difference between the two group, however, dual antiplatelet therapy group showed greater reductions than monotherapy group (P<0.05). Conclusion: Compared with clopidogrel monotherapy, clopidogrel plus aspirin can improve the vascular endothelial function and reduce the inflammatory reaction in patients after drug-eluting stent implantation.

Key words： Clopidogrel Aspirin Dual antiplatelet Drug-eluting stent Endothelial function Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Qing
	YE Hong

Cite this article:

GUO Qing,YE Hong. Effects of Monotherapy and Dual Antiplatelet Therapy on Vascular Endothelial Function and Inflammatory Factors after Drug-eluting Stent Implantation[J]. HeBei Med, 2018, 24(2): 235-239.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.02.014 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I2/235

[1] Liu M, Chen J, Huang D,et al.Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation:a meta-analysis of 3 randomized controlled trials[J].Cardiovasc Pharmacol,2014,64(1):41~46.
[2] Van Beusekom HM, Sorop O, Batenburg WW, et al. Specific coronary drug-eluting stents interference with distal microvascular function after single stent implantation in pigs[J].JACC Cardioavasc interventions,2010,3(7):723~730.
[3] Van Beusekom HM, Sorop O, Van den Heuvel M,et al. Endothelial function rather than endothelial restoration is altered in pacitaxel-as compared to bare metal-,sirolimus and tacrolimus-eluting stents[J]. Eurointervention,2010,6(1): 117~125.
[4] Minha S, Pichard AD, Waksman R. In-stent restenosis of drug-eluting stents[J]. Future Cardiology, 2013,9(5):721~731.
[5] Papp J,Kenyeres P,Toth K. Clinical importance of antiplatelet drugs in cardiovascular diseases[J]. Clin Hemorheol Microcirc,2013,53(1):81~96.
[6] Ostad MA, Nick E,Paixao-Gatinho V, et al. Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study[J]. Clin Res Cardiol, 2010,100(1):29~36.
[7] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Am Coll Cardiol,2013,61(2):78~140.
[8] Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension[J].Glob Cardiol Sci Pract,2013,2014(2):62~78.
[9] Phillips SA, Andaku DK, Mendes RG, et al. Exploring Vascular Function Biomarkers: Implications for Rehabilitation[J]. Braz Cardiovasc Surg, 2017 ,32(2):125~135.
[10] Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus and paclitaxel-eluting stents in humans[J]. Circulation,2014,129(2): 211~223.
[11] Papp J, Kenyeres P, Toth K. Clinical importance of antiplatelet drugs in cardiovascular diseases[J]. Clin Hemorheol Microcirc, 2013,53(1):81~96.
[12] Fong LY, Ng CT, Zakaria ZA, et al. Asiaticoside Inhibits TNF-a-Induced Endothelial Hyperpermeability of Human Aortic Endothelial Cells[J].Phytother Res, 2015 ,29(10):1501~1508.
[13] Sara JDS, Prasad M, Zhang M, et al.High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease[J].Am Heart,2017,190(2):1~11.
[14] Dosh K, Berger PB, Marso S, et al. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention[J]. Circ Cardiovasc Interv, 2009,2(6):503~512.